Longitudinal Study of Brain Amyloid imaGing in MEMENTO

Phase 3 Completed 448 enrolled University Hospital, Bordeaux Avid Radiopharmaceuticals · collab Fondation Plan Alzheimer · collab GE Healthcare · collab

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

A Multicenter national longitudinal cohort study including at least 800 individuals consecutively recruited from French Research Memory Centers and followed-up over 24 month and included in Memento.

Timeline

Start: 2014-06-10
Primary completion: 2019-10-09
Completion: 2019-10-09

Publications

Ackley S, Calmasini C, Bouteloup V, Hill-Jarrett TG, Swinnerton KN, Chene G, Dufouil C, Glymour MM; MEMENTO Cohort Study Group and DPUK. Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort. Neurology. 2024 Mar 26;102(6):e208054. doi: 10.1212/WNL.0000000000208054. Epub 2024 Feb 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Flutemetamol	Diagnostic / imaging agent	—	—
Subject	florbetapir	Diagnostic / imaging agent	—	—

Longitudinal Study of Brain Amyloid imaGing in MEMENTO

Summary

Timeline

Publications

Drugs

Indications